TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
Brief Summary: The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure. Vascular filling may also have an impact on tolerability of enteral nutrition. The earliness and quantity of calories provided by enteral nutrition may have an impact on morbidity and mortality. This study will asses the effects of volume expansion on hemodynamics and tolerability of enteral nutrition in patients with severe sepsis. A Data Monitoring Committee will review regularly safety data of the study.


Options:
A: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl
B: Intervention Type: DRUG; Name: HyperHAES vs. RA-solution/NaCl; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A
D: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Management of Intracapsular Fractures of the Proximal Femur. A Prospective, Randomized Trial of Two Parallel Screws and Hemiarthroplasty
Brief Summary: An estimated 1.6 million patients sustain a hip fracture every year, about half of these are intracapsular femoral neck fractures. A femoral neck fracture is a life changing event for any patient, and the risk of disability, increased dependence and death is substantial. The main treatment options for displaced femoral neck fractures are internal fixation and arthroplasty. It is established that there are more complications and reoperations after internal fixation, but there is no consensus about which procedure that gives best functional results.


Options:
A: Intervention Type: PROCEDURE; Name: Bipolar hemiarthroplasty (Charnley/Hastings); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Internal fixation with two parallel screws (Olmed); Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Device: Cemented hemiarthroplasty | Arm Label: Treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: Cemented total hip arthroplasty | Intervention Type: DEVICE; Name: Cemented total hip arthroplasty; Assigned to Arm(s): Treatment group | Intervention Type: DEVICE; Name: Cemented hemiarthroplasty; Assigned to Arm(s): Control group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Total hip arthroplasty | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Hemi-arthroplasty | Intervention Type: DEVICE; Name: Total hip arthroplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Hemi-arthroplasty; Assigned to Arm(s): 2
D: Arm Label: Conservative Treatment for Impacted Femoral Neck Fracture; Type: EXPERIMENTAL; Interventions: Procedure: Surgical Treatment for Impacted Femoral Neck Fracture | Intervention Type: PROCEDURE; Name: Surgical Treatment for Impacted Femoral Neck Fracture; Assigned to Arm(s): Conservative Treatment for Impacted Femoral Neck Fracture

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures
Brief Summary: This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures
Brief Summary: This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): B
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: levetiracetam | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: levetiracetam; Assigned to Arm(s): A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)
Brief Summary: The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.


Options:
A: Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 90 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 90 mg QD
B: Arm Label: 001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rabeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Rabeprazole; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): 001
C: Arm Label: On demand 20 mg esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Continuous 20 mg esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Continuous 20 mg esomeprazole, On demand 20 mg esomeprazole
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR QD | Intervention Type: DRUG; Name: Dexlansoprazole MR QD; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy
Brief Summary: This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.


Options:
A: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis
Brief Summary: This trial was conducted in the United States of America (USA). This trial aimed to evaluate safety and efficacy of 17-beta Estradiol in the treatment of atrophic vaginitis.


Options:
A: Arm Label: Ospemifene; Type: EXPERIMENTAL; Interventions: Drug: Ospemifene | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ospemifene; Assigned to Arm(s): Ospemifene | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: estradiol, 10 mcg; Assigned to Arm(s): N/A
C: Arm Label: Treatment with transdermal 17β-estradiol; Type: EXPERIMENTAL; Interventions: Drug: 17β-estradiol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: 17β-estradiol | Intervention Type: DRUG; Name: 17β-estradiol; Assigned to Arm(s): Control, Treatment with transdermal 17β-estradiol
D: Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of 17-Beta Estradiol 10 Micrograms and 25 Micrograms (Vagifem) Doses in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis
Brief Summary: This trial was conducted in the United States of America (USA). This trial aimed for a comparison between the effect of two different doses of estradiol on parameters related to efficacy and safety.


Options:
A: Arm Label: Treatment with transdermal 17β-estradiol; Type: EXPERIMENTAL; Interventions: Drug: 17β-estradiol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: 17β-estradiol | Intervention Type: DRUG; Name: 17β-estradiol; Assigned to Arm(s): Control, Treatment with transdermal 17β-estradiol
B: Intervention Type: DRUG; Name: estradiol gel; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: estradiol, 10 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Synthetic Conjugated estrogens, B | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Synthetic Conjugated estrogens, B; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized,Double-Blind , Placebo-Controlled Crossover Trial of Antivirals for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Co-infected Persons
Brief Summary: Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The evidence suggests that HSV is an important co-factor in HIV transmission.

The trial's purpose is to assess the reduction in HIV systemic and mucosal replication associated with valacyclovir for suppression of HSV-2 reactivation.

This randomized, double-blind, placebo controlled crossover trial of 20 HIV/HSV-2 co-infected women assessed the effects of daily valacyclovir on HIV-1 levels in blood and body fluids.


Options:
A: Arm Label: Standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: valacyclovir | Arm Label: High-dose; Type: EXPERIMENTAL; Interventions: Drug: acyclovir | Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): High-dose | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): Standard dose
B: Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): N/A
C: Arm Label: Acyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Generic acyclovir | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Generic acyclovir; Assigned to Arm(s): Acyclovir | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Valacyclovir, Drug: Matching Placebo | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): I

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized,Double-Blind , Placebo-Controlled Crossover Trial of Antivirals for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Co-infected Persons
Brief Summary: Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The evidence suggests that HSV is an important co-factor in HIV transmission.

The trial's purpose is to assess the reduction in HIV systemic and mucosal replication associated with valacyclovir for suppression of HSV-2 reactivation.

This randomized, double-blind, placebo controlled crossover trial of 20 HIV/HSV-2 co-infected women assessed the effects of daily valacyclovir on HIV-1 levels in blood and body fluids.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Valacyclovir, Drug: Matching Placebo | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): I
B: Arm Label: Trivalent MRKAd5 HIV-1 gag/pol/nef; Type: EXPERIMENTAL; Interventions: Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo | Intervention Type: BIOLOGICAL; Name: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose); Assigned to Arm(s): Trivalent MRKAd5 HIV-1 gag/pol/nef | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Acyclovir (ACV); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Falls, Fracture, and Osteoporosis Risk Control Evaluation (FORCE) Study: A Randomized Controlled Trial With Community Partnerships in Northern Ontario
Brief Summary: Falls and osteoporosis-related fractures cause substantial morbidity and mortality in the elderly, and are an increasingly important public health concern. A comprehensive multidisciplinary and integrated community-based approach is needed to identify and manage the population at highest risk of these complications. Unfortunately, current gaps in continuity of care and health intervention result in a sub-optimal state of health service for these individuals. The Falls, Fracture and Osteoporosis Risk Control and Evaluation (FORCE) Study is a two-year randomized controlled trial evaluated on the effect of coordinated community-based, multidisciplinary approach for fall and fracture prevention in Sault Ste. Marie.


Options:
A: Arm Label: Home-based Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based exercise | Arm Label: Education; Type: EXPERIMENTAL; Interventions: Behavioral: Education | Arm Label: Exercise plus education; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise plus Education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based exercise; Assigned to Arm(s): Home-based Exercise | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education | Intervention Type: BEHAVIORAL; Name: Exercise plus Education; Assigned to Arm(s): Exercise plus education
B: Intervention Type: BEHAVIORAL; Name: Falls, Fractures & Osteoporosis Risk Assessment & Management; Assigned to Arm(s): N/A
C: Arm Label: Multifactorial intervention; Type: EXPERIMENTAL; Interventions: Device: multifactorial | Intervention Type: DEVICE; Name: multifactorial; Assigned to Arm(s): Multifactorial intervention
D: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Multifactorial Falls Prevention Program; Type: EXPERIMENTAL; Interventions: Other: On-site exercise, Other: home-based exercise, Other: Educational and behavioural, Other: Management of modifiable risk factors | Intervention Type: OTHER; Name: On-site exercise; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: home-based exercise; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Educational and behavioural; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Management of modifiable risk factors; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Falls, Fracture, and Osteoporosis Risk Control Evaluation (FORCE) Study: A Randomized Controlled Trial With Community Partnerships in Northern Ontario
Brief Summary: Falls and osteoporosis-related fractures cause substantial morbidity and mortality in the elderly, and are an increasingly important public health concern. A comprehensive multidisciplinary and integrated community-based approach is needed to identify and manage the population at highest risk of these complications. Unfortunately, current gaps in continuity of care and health intervention result in a sub-optimal state of health service for these individuals. The Falls, Fracture and Osteoporosis Risk Control and Evaluation (FORCE) Study is a two-year randomized controlled trial evaluated on the effect of coordinated community-based, multidisciplinary approach for fall and fracture prevention in Sault Ste. Marie.


Options:
A: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
C: Intervention Type: BEHAVIORAL; Name: Falls, Fractures & Osteoporosis Risk Assessment & Management; Assigned to Arm(s): N/A
D: Arm Label: 1 (physician-only); Type: EXPERIMENTAL; Interventions: Other: Information letters | Arm Label: 2 (physician/patient); Type: EXPERIMENTAL; Interventions: Other: Information letters | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Information letters; Assigned to Arm(s): 1 (physician-only), 2 (physician/patient)

Answer: C